The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry
Author(s)
Type
Journal Article
Abstract
Pulmonary hypertension (PH) is classified into five groups based on disease etiology but there is only limited information on the prognostic value of exercise testing in non-group 1 PH. In group 1 PH, the incremental shuttle walking test (ISWT) distance has been shown to correlate with pulmonary hemodynamics and predict survival without a ceiling effect. This study assessed the ISWT in non-group 1 PH. Data were retrieved from the ASPIRE Registry (Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre) for consecutive patients diagnosed with PH. Patients were required to have been systematically assessed as group 2–5 PH and to have a baseline ISWT within three months of cardiac catheterization. Patients were stratified according to incremental shuttle walk test distance (ISWD) and ISWT distance percent predicted (ISWD%pred). A total of 479 patients with non-group 1 PH were identified. ISWD and ISWD%pred correlated significantly with symptoms and hemodynamic severity. ISWD and ISWD%pred predicted survival with no ceiling effect. The test was prognostic in groups 2, 3, and 4. ISWD and ISWD%pred and change in ISWD and ISWD%pred at one year were all significant predictors of outcome. In patients with non-group 1 PH the ISWT is a simple non-invasive test that is easy to perform, is predictive of survival at baseline and follow-up, reflects change, and can be used in the assessment of PH of any etiology.
Date Issued
2019-04
Date Acceptance
2019-04-09
Citation
Pulmonary Circulation, 2019, 9 (2), pp.1-9
ISSN
2045-8932
Publisher
Wiley
Start Page
1
End Page
9
Journal / Book Title
Pulmonary Circulation
Volume
9
Issue
2
Copyright Statement
© The Author(s)
http://creativecommons.org/licenses/by/4.0/Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
http://creativecommons.org/licenses/by/4.0/Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
License URL
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000469506100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
Subjects
ARTERIAL-HYPERTENSION
BOSENTAN
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
CLINICAL-TRIALS
disease severity
DISTANCE
END-POINT
exercise testing
HEART-FAILURE
HEMODYNAMICS
Life Sciences & Biomedicine
METAANALYSIS
prognosis
PROGNOSTIC-SIGNIFICANCE
Respiratory System
Science & Technology
SURVIVAL
Publication Status
Published
Date Publish Online
2019-05-01